Get the Stockscreener App
5.04
4.55%
-0.24
After Hours:
5.00
-0.04
-0.79%
Nuvectis Pharma Inc stock is traded at $5.04, with a volume of 63,739.
It is down -4.55% in the last 24 hours and down -35.96% over the past month.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
See More
Previous Close:
$5.28
Open:
$5.22
24h Volume:
63,739
Relative Volume:
0.37
Market Cap:
$97.38M
Revenue:
-
Net Income/Loss:
$-22.38M
P/E Ratio:
-3.2516
EPS:
-1.55
Net Cash Flow:
$-15.54M
1W Performance:
-1.18%
1M Performance:
-35.96%
6M Performance:
-21.50%
1Y Performance:
-37.93%
1-Day Range:
$4.99
$5.4799
1-Week Range:
$4.8483
$5.4799
52-Week Range:
$4.6106
$12.10
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Name
Nuvectis Pharma Inc
Sector
Industry
Phone
360-837-7232
Address
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
5.04 | 97.38M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-13-22 | Initiated | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Stock (NVCT) Latest News
Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know - MSN
Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - MSN
Nuvectis Pharma stock hits 52-week low at $4.7 amid market challenges - Investing.com Australia
Nuvectis Pharma stock hits 52-week low at $4.7 amid market challenges By Investing.com - Investing.com South Africa
Nuvectis sinks after early-stage data for ovarian cancer therapy - MSN
Nuvectis pharma officer Enrique Poradosu buys $9,980 in stock By Investing.com - Investing.com Australia
Ron Bentsur Buys Handful Of Shares In Nuvectis Pharma - Simply Wall St
Insider Buying: Nuvectis Pharma Inc (NVCT) Chairman & CEO Acquires Shares - GuruFocus.com
Nuvectis pharma officer Enrique Poradosu buys $9,980 in stock - Investing.com
Vitalli ends work on Daewoong asset; Alector’s $50M loan - Endpoints News
Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Buys 20,000 Shares - MarketBeat
Nuvectis pharma chairman buys $98,400 in common stock By Investing.com - Investing.com Canada
Nuvectis pharma chairman buys $98,400 in common stock - Investing.com
Nuvectis Pharma reports data from Phase 1b study of NXP800 - Yahoo Finance
Market Alert: Nuvectis Pharma reports promising data for NXP800 in Phase 1b; Advancing Towards Higher Dose Cohort - The Globe and Mail
500: Something went wrong - Investing.com Canada
Why Is Nuvectis Pharma Stock Trading Lower On Thursday?Nuvectis Pharma (NASDAQ:NVCT) - Benzinga
NVCT stock touches 52-week low at $5.05 amid market fluctuations - Investing.com India
U.S. Stock market: Nuvectis Pharma declined by 40.58% while Sow Good was down by 55.30% during mid day trading - Business Upturn
Nuvectis stock sinks on data for cancer drug (NVCT:NASDAQ) - Seeking Alpha
Nuvectis Pharma Stock Plummets on Updated Data for Ovarian Cancer Study - MarketWatch
Nuvectis Pharma Inc trading resumes - TipRanks
U.S. Stock market: Nuvectis Pharma saw a sharp decline of 53.89% while AgEagle Aerial Systems surged by 133.74% in early trading - Business Upturn
Nuvectis Pharma Reports Encouraging NXP800 Interim Data - GlobeNewswire
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase - The Bakersfield Californian
Nuvectis Pharma's NXP800 Shows Promise in Phase 1b Cancer Trial, New Dosing Success | NVCT Stock News - StockTitan
Trading (NVCT) With Integrated Risk Controls - Stock Traders Daily
Nuvectis Pharma (NASDAQ:NVCT) Announces Third Quarter 2024 Financial Results and Business Updates - Defense World
Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Nuvectis Pharma's VP Michael Carson sells $22.5k in stock - Investing.com
Nuvectis Pharma's VP Michael Carson sells $22.5k in stock By Investing.com - Investing.com UK
FY2024 EPS Estimates for Nuvectis Pharma Raised by Analyst - Defense World
FY2024 EPS Estimate for Nuvectis Pharma Increased by Analyst - MarketBeat
Analysts Offer Predictions for Nuvectis Pharma Q1 Earnings - Defense World
Roth Capital Comments on Nuvectis Pharma Q1 Earnings - MarketBeat
Nuvectis Pharma Reports Improved Q3 Financials and Clinical Progress - TipRanks
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire
Trend Tracker for (NVCT) - Stock Traders Daily
Nuvectis Pharma's NXP900 Shows Promise in NSCLC Treatment, NXP800 Data Update Anticipated - Vancity Buzz
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update - Business Wire
NVCTNuvectis Pharma, Inc. Latest Stock News & Market Updates - StockTitan
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times
Nuvectis Pharma Announces Upcoming Presentations for NXP900 - GlobeNewswire
Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
Marshall Wace LLP Has $214,000 Stock Holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World
Nuvectis Pharma Inc Stock (NVCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):